SPIRIT III

Related by string. * Spirits . spirited . spirits . Spirited . spiriting . Spirit . spirit . SPIRITS : Holy Spirit . Spirited Away . Teen Spirit . mean spirited . evil spirits . Prudential Spirit . Spirit Squad . SPIRIT / iii . Iii . IIIs . IIID . IIi : Star Wars Episode III . Phase III clinical trials . Phase III trials . Phase III clinical . Guitar Hero III . Tha Carter III . pivotal Phase III . Episode III Revenge * *

Related by context. All words. (Click for frequent words.) 72 SPIRIT IV 71 ENDEAVOR IV 70 TAXUS ATLAS 68 ENDEAVOR III 67 Long Lesion 67 EVEREST II 67 SPIRIT FIRST 67 placebo controlled clinical 67 multicenter clinical 67 randomized controlled clinical 67 Endeavor drug eluting 66 Edge STudy 66 randomized Phase III 66 NEVO RES 65 everolimus eluting stent 65 placebo controlled Phase III 65 Endovascular Valve Edge 65 multicenter randomized controlled 65 XIENCE V demonstrated 65 TAXUS IV 65 randomized clinical 65 TAXUS Stent 65 ENDEAVOR II 64 RE LY ® 64 CARE HF 64 multicenter randomized clinical 64 HORIZONS AMI trial 64 XIENCE V 64 NO# [002] 64 PERSEUS 64 TAXUS Liberte Stent 64 phase IIa 63 CUSTOM III 63 ABSORB trial 63 Coronary Stent 63 XIENCE V Stent System 63 RE LY 63 COMFORT II 63 placebo controlled Phase 63 TAXUS VI 63 CYPHER ® Stent 63 Phase IIIb clinical 63 Endeavor stent 63 ACUITY trial 63 PROMUS Element Stent 63 phase IIa clinical 63 TG MV 63 ZoMaxx 63 NEVO 63 BRIM3 63 landmark ATHENA 63 multicentre randomized 62 paclitaxel eluting stents 62 multicenter prospective 62 CYPHER R Sirolimus eluting 62 everolimus eluting stents 62 phase IIb clinical 62 TAXUS TM 62 Phase IIIb 62 PRIMO CABG2 62 randomized controlled multicenter 62 TAXUS R 62 prospective randomized controlled 62 EURIDIS 62 TAXUS 62 TAXUS stent 62 SYNTAX trial 62 PERSEUS clinical program 62 MADIT II 62 nonrandomized 62 Randomized Evaluation 62 confirmatory clinical 62 SORT OUT III 62 AVADO 62 XIENCE V PROMUS Stent 61 Phase Ib clinical 61 Xience V 61 prospective multicenter randomized 61 TAXUS Liberte Long 61 TAXUS Liberte stent 61 sirolimus eluting stents 61 randomized Phase IIb 61 prospective randomized 61 multicenter multinational 61 AVERROES 61 TAXUS Express2 61 Intervention Effectiveness 61 MERLIN TIMI 61 NEVO ™ 61 ENESTnd 61 pharmacokinetic PK 61 EDEMA3 61 Pivotal Clinical Trial 61 prospective multicenter 61 multicenter Phase 61 TAXUS Liberte 61 TEMSO 61 CYPHER ® Sirolimus eluting 61 DASISION 61 comparing XIENCE V 61 Pivotal Trial 61 double blinded randomized 61 Pivotal Phase III 61 PROMUS Element Everolimus Eluting 61 Acute Myocardial Infarction 61 ACCORD Lipid 60 Sorafenib HCC Assessment 60 Phase III clinical 60 XIENCE V Everolimus Eluting 60 SABCS 60 multicenter randomized Phase 60 CYPHER R Stent 60 MEND CABG 60 Combination REOLYSIN R 60 Phase III 60 ONTARGET 60 Transcatheter Cardiovascular Therapeutics TCT 60 Taxus Stent 60 Phase 2a clinical 60 registrational Phase 60 GetGoal Phase III 60 Platelet Inhibition 60 GAMMAGARD 60 RECORD1 60 Phase 2b study 60 mm Stent 60 viral kinetic 60 Pivotal Phase 60 MIST II 60 APPRAISE 60 CLARITY study 60 Prostate Cancer Prevention 60 Phase 2b clinical 60 Carotid Revascularization Endarterectomy vs. 60 Multicenter Automatic Defibrillator Implantation 60 PFO migraine 60 ExTRACT TIMI 60 multicenter randomized 60 active comparator 60 multicenter phase 60 AIM HIGH 60 TAXUS ® 60 HORIZONS AMI 60 sirolimus eluting stent 60 carotid stenting 60 Phase Ib II 60 ENDEAVOR 60 TAXUS Liberté 60 LUX Lung 60 STRIDE PD 60 multicenter placebo controlled 60 angiographic outcomes 59 Randomized controlled 59 Endeavor Drug Eluting 59 drug eluting stent DES 59 TAXUS Element Stent System 59 multicenter 59 Coronary Stent System 59 recurrent GBM 59 multicenter Phase III 59 TAXUS V 59 secondary efficacy endpoints 59 oral FTY# 59 HCV RESPOND 2 59 randomized multicenter 59 CAMMS# 59 Resolute DES 59 Zilver PTX 59 PROMUS ® 59 workhorse lesions 59 ABSORB clinical 59 ongoing Phase 1b 59 Stent System 59 PRECiSE 59 clinical trial 59 NSABP B 59 APEX PD 59 Phase III VISTA 59 controlled multicenter 59 Dialysis Outcomes 59 randomized controlled 59 Sirolimus Eluting Coronary Stent 59 randomized clinical trials 59 EOquin TM 59 Prostate Lung Colorectal 59 Amrubicin 59 Clinical Outcomes Utilizing Revascularization 59 Phase IIa clinical 59 BRIM2 59 Clinical Trial Results 59 XIENCE V stent 59 ADMIRE HF 59 Drug Eluting Stent 59 stent DES 59 Phase III placebo controlled 59 Val HeFT 59 Phase III ThermoDox 59 randomized trials 59 Phase IIb clinical 59 Prostate AdenoCarcinoma Treatment 59 trials RCTs 59 PROTECT AF 59 Sibutramine Cardiovascular Outcomes 59 ToGA 59 evaluating REVLIMID 58 dose escalation clinical 58 Edwards SAPIEN valve 58 phase IIb 58 SYNERGY Stent 58 multicenter randomized double 58 TAXUS ATLAS Small 58 Ovarian Cancer Screening 58 randomized placebo controlled 58 Tryton Side Branch 58 substudy 58 subanalysis 58 TAXUS Express Stent 58 Digital Mammographic Imaging 58 Phase IIB 58 evaluating mipomersen 58 Phase III randomized 58 randomized multicenter trial 58 mg/m2 cohort 58 TM Drug Eluting 58 Prospective Randomized 58 VADT 58 teriflunomide 58 Phase 2b kidney transplant 58 PROMUS TM 58 MADIT CRT 58 PROMUS R 58 TAXUS Element Paclitaxel Eluting 58 Phase 2b 58 TRITON TIMI 58 Randomised 58 EuroPCR 58 Phase 1a clinical 58 ENDEAVOR IV clinical 58 V Everolimus Eluting Coronary 58 Phase III pivotal 58 Rosuvastatin 58 EchoCRT 58 placebo controlled randomized 58 CUSTOM II 58 Transcatheter Cardiovascular Therapeutics 58 pivotal Phase III 58 multicenter Phase II 58 BCIRG 58 Phase III AFFIRM 58 ABSORB 58 IMPROVE HF 58 PROMUS 58 carotid endarterectomy CEA 58 dose escalation trial 58 Myocardial Infarction Study 58 paclitaxel eluting stent 58 ORENCIA R 58 phase Ib 58 Phase 1b trial 58 dose escalation Phase 58 Xience V stent 58 Phase III Trial 58 HCV SPRINT 58 Initiated Phase 58 PRIMO CABG 58 PARTNER Trial 58 randomized controlled clinical trials 58 Clinical Antipsychotic Trials 58 ARIXTRA 58 Randomized Clinical Trial 58 ILLUMINATE 57 randomized Phase 2b 57 PRE SURGE 57 ACTEMRA 57 SYMMETRY trial 57 ARCOXIA 57 Phase III Psoriasis 57 Events MACE 57 XIENCE TM 57 Phase Ib study 57 Randomized Study 57 NSABP C 57 randomized multicenter Phase III 57 RIO Lipids 57 TRA 2P 57 SUCCEED trial 57 Stenting 57 Drug Eluting Stents 57 axitinib 57 multicenter randomized placebo controlled 57 subgroup analyzes 57 ATACAND 57 Screening Trial 57 ACRIN 57 Phase 2b trial 57 clinical endpoints 57 ROCKET AF 57 placebo controlled 57 TMC# C# 57 RESOLUTE 57 ANCHOR trial 57 Augment Injectable 57 Phase 1b 57 SYNTAX 57 prospective multicentre 57 carotid artery stenting 57 Phase 1b clinical 57 BOLDER II 57 phase IIIb 57 Acute Decompensated Heart Failure 57 Randomized Phase 57 PreCISe 57 recurrent malignant glioma 57 ASTEROID 57 Acute Ischemic Stroke 57 ADVANCE PD 57 Stenting Trial CREST 57 Oral Fingolimod 57 ORAL Sync 57 REMINYL ® 57 Phase IIb 57 randomized blinded 57 PROactive study 57 Phase III HEAT 57 EDEMA4 57 non inferiority 57 Eluting Coronary Stent System 57 multicenter trials 57 First Patient Enrolled 57 Azedra 57 placebo controlled studies 57 drug eluting stent 57 fidaxomicin Phase 3 57 label multicenter 57 Medtronic Endeavor 57 Pooled Analysis 57 drug eluting coronary stent 57 Stent Thrombosis 57 Phase IIb III 57 CATIE AD 57 ACTEMRA TM 57 ENDEAVOR clinical 57 UPLYSO 57 oral ridaforolimus 57 Randomized Phase II 57 II Clinical Trial 57 CAPRIE 56 noninferiority 56 Resolute drug eluting 56 PRESEPT 56 ABCSG 56 relapsed refractory multiple myeloma 56 metastatic HRPC 56 Pirfenidone 56 Liberte TM 56 assessing T DM1 56 Phase 1a 56 CALGB 56 Multicenter 56 rALLy clinical trial 56 NCT# ClinicalTrials.gov 56 tanespimycin 56 Phase III Pivotal 56 placebo controlled trials 56 CALGB # [002] 56 Everolimus Eluting Coronary Stent 56 Multicenter Randomized 56 REALITY Trial 56 Phase IIa trial 56 randomized Phase 56 placebo controlled multicenter 56 RE SURGE 56 pivotal Phase 56 Cypher Stent 56 Phase III psoriasis 56 Pharmacokinetic 56 sirolimus eluting 56 phase 2a 56 OLYMPIA registry 56 fidaxomicin Phase 56 Sirolimus eluting Coronary Stent 56 LUMINATE 56 MADIT 56 NEVO TM 56 TAXUS Express 56 TAXUS Element Stent 56 Phase IIb trial 56 Screening Trial DMIST 56 Randomized Double Blind 56 patients undergoing percutaneous 56 DU #b 56 zotarolimus eluting stent 56 dosing cohorts 56 Taxus stent 56 fully bioabsorbable 56 ALSYMPCA 56 randomized controlled Phase 56 NCCTG N# 56 CYPHER Stent 56 phase IIb study 56 Stent Restenosis 56 ASCO Breast Cancer 56 evaluating tivozanib 56 Percutaneous Coronary Intervention 56 Clinical Trial 56 Sirolimus eluting 56 Coronary Artery Bypass Graft 56 Tavocept 56 bioabsorbable stent 56 Prospective Randomized Trial 56 Phase IIa 56 EXPLORE Xa 56 PRECISE 56 multicentre 56 multicenter study 56 Cypher Sirolimus 56 prospective observational 56 IMPACT DCM 56 COU AA 56 Topline Results 56 Phase Ib IIa 56 riociguat 56 trastuzumab emtansine T DM1 56 Phase 2a 56 prospective nonrandomized 56 Long Term Efficacy 56 PROSTVAC TM 56 NSABP 56 Ovarian PLCO Cancer 55 Zemplar Capsules 55 Randomized Phase III 55 XIENCE 55 MADIT CRT trial 55 Prospective Multicenter 55 Phase 2a trial 55 prospectively defined 55 PROactive Study 55 Pharmacokinetic parameters 55 LCP Tacro 55 randomized double 55 pharmacodynamic effects 55 paclitaxel eluting 55 BARI 2D 55 phase IIb trial 55 CTRC AACR San Antonio 55 Heart Failure Trial 55 retrospective observational study 55 Relapsed Multiple Myeloma 55 PLCO 55 Breaking Clinical Trials 55 PROVENGE ® 55 Phase IIIb study 55 Medtronic CoreValve 55 Phase #b/#a clinical 55 rALLy trial 55 AIR CF1 55 Zenvia Phase III 55 dose escalation phase 55 Meta analyzes 55 Diabetic Macular Edema 55 MGd 55 AIR CF2 55 Thrombolysis 55 blinded placebo controlled 55 preclinical efficacy 55 alvespimycin 55 Drug Eluting Stent System 55 masked placebo controlled 55 brivaracetam 55 NYHA Class II 55 telaprevir dosing 55 AIR2 Trial 55 TELCYTA 55 TAXUS ARRIVE 55 Drug Eluting 55 crizotinib PF # 55 Phase III Clinical Trial 55 Angiographic 55 GOUT 55 CLARITY TIMI 55 bazedoxifene conjugated estrogens 55 ARBITER 6 55 Phase IIb trials 55 Taxus 55 Phase III trials 55 AACR NCI EORTC 55 elotuzumab 55 TAXUS Express2 Paclitaxel Eluting 55 prospective randomized multicenter 55 Study Evaluating 55 Eluting Stent 55 Therapeutics TCT scientific 55 MitraClip 55 unfractionated heparin UFH 55 Elagolix 55 NATRECOR R 55 Phase 2b Clinical Trial 55 CANCIDAS 55 Phase III Clinical Trials 55 blinded randomized 55 prospective randomized placebo 55 sipuleucel T 55 Randomized Controlled 55 relapsing remitting MS RRMS 55 UKPDS 55 Initiate Phase II 55 Refractory Angina 55 NICE SUGAR 55 oral deforolimus 55 Dose Ranging 55 relapsed MM 55 Pharmacokinetic PK 55 Pivotal Study 55 rivaroxaban 55 atrasentan 55 prospective multicenter study 55 ONTARGET R 55 Aggressive Drug Evaluation 55 GISSI HF 55 Phase Ia 55 Phase III ADT 55 INCB# [001] 55 Plicera 55 ORACLE MS 55 drug eluting stents 54 catheter occlusion 54 LymphoStat B 54 Randomized Double Blind Placebo 54 Clinical Study 54 Metastatic Melanoma 54 Phase #/#a 54 Bare Metal Stent 54 RIO Diabetes 54 CYPHER R stent 54 vorinostat 54 Bivalirudin 54 palifosfamide Zymafos TM 54 drug eluting coronary stents 54 COPERNICUS 54 Major Adverse Cardiac 54 LibiGel Phase III 54 oral rivaroxaban 54 Androxal TM 54 PROPEL trial 54 Delcath Phase III 54 CHAMPION PCI 54 rosuvastatin 54 treatment naive genotype 54 Betaferon ® 54 Express2 TM paclitaxel eluting 54 CoFactor 54 morphometric vertebral fractures 54 Active Ulcerative Colitis 54 ® Everolimus Eluting 54 blinded randomized placebo controlled 54 double blind placebo 54 Phase 2a Clinical Trial 54 ICON7 54 GORE VIABAHN Endoprosthesis 54 enzastaurin 54 ASCEND HF 54 IL# PE#QQR 54 secondary endpoint 54 NEO3 54 BR.# 54 azilsartan medoxomil 54 anti arrhythmic drug 54 EORTC 54 multicenter clinical trials 54 PIX# [002] 54 Phase Ib 54 Multicenter Phase 54 Endeavor Resolute 54 MIVI III 54 Severe Sepsis 54 randomized 54 Completes Enrollment 54 PROMUS Element 54 Cardiac Resynchronization Therapy 54 Valsartan 54 tolvaptan 54 evaluable subjects 54 Monitoring ABPM 54 Thorough QT 54 DAPT 54 Radiation Therapy Oncology 54 pharmacokinetics PK 54 Carotid 54 RE MODEL 54 HoFH 54 Newly Diagnosed Multiple Myeloma 54 TRANSFORMS 54 recurrent glioblastoma multiforme 54 Traficet EN 54 Taxus Liberte stent 54 Paclitaxel eluting 54 GORE TAG Device 54 Ophena TM 54 Angiox R 54 EQUIP OB 54 fosbretabulin 54 dose cohorts 54 Clinical Oncology Annual Meeting 54 candesartan cilexetil 54 Raloxifene Evaluation MORE 54 Drug Eluting Coronary Stent 54 Endeavor DES 54 Intervention Effectiveness CATIE 54 Genous stent 54 Medtronic Endeavor stent 54 PEGylated interferon beta 1a 54 number NCT# ClinicalTrials.gov 54 prospective observational cohort 54 ADAGIO study 54 ACTIVE W 54 MEND CABG II 54 Embolic Protection Device 54 FOLPI 54 confirmatory Phase III 54 CHARISMA trial 54 Nymox NX 54 alvimopan 54 Paclitaxel Eluting Coronary Stent 54 R# #mg BID 54 multicentre randomized double 54 LCP AtorFen 54 CYPHER ® 54 USpella 54 ORENCIA ® 54 HepaSphere 54 National Emphysema Treatment 54 Myocardial Infarction 54 Phase IIB clinical 54 CYPHER R Sirolimus Eluting 54 bardoxolone 54 carotid artery stenting CAS 54 CONQUER OB 54 Aryplase 54 Bare Metal Stents 54 galiximab 54 Endeavor Resolute DES 54 SIMPADICO 54 confirmatory Phase 3 54 olaparib 54 TIMI Study Group 54 IIa clinical 54 Osteoporotic Fractures 54 Glucosamine Chondroitin Arthritis 54 CRESTOR #mg 53 dose cohort 53 neoadjuvant 53 IMPROVE IT 53 Patient Outcomes 53 HYVET 53 Hematology Meeting 53 Demonstrates Sustained 53 MitraClip device 53 arzoxifene 53 CIMZIA ™ 53 EMPOWER ™ 53 Intracranial Aneurysms 53 diabetic neuropathic pain 53 ACCORD COPD 53 Cloretazine ® 53 SCD HeFT 53 blind multicenter 53 elagolix 53 PROTECT II 53 PRoFESS 53 Meets Primary Endpoint 53 RE LY trial 53 PF # [001] 53 phase Ib clinical 53 IIa clinical trial 53 NeuroFlo 53 comparing alemtuzumab 53 double blinded placebo 53 Impella 53 Heparin Bioactive Surface 53 Randomized 53 registrational trial 53 Non inferiority 53 PANVAC VF 53 Raloxifene STAR 53 STEALTH C 53 MitraClip R 53 dose escalation 53 CombAT 53 unblinding 53 OBPM 53 EDEMA3 trial 53 CORD II 53 JAK inhibitor 53 placebo controlled clinical trials 53 phase III ACCLAIM 53 NLX P# 53 ELCAP 53 MoxDuo TM IR 53 analgesic efficacy 53 eculizumab 53 IMPACT IMmunotherapy 53 Phase IIa trials 53 efficacy endpoints 53 FAME Study 53 Clinical Efficacy 53 dabigatran etexilate 53 European Sepsis Trial 53 Xience Prime 53 Group RTOG 53 acute PAO 53 elective PCI 53 clinical trials 53 Heart Failure Therapies 53 blinded randomized controlled 53 Novolimus 53 Carotid Stenting 53 Acute Coronary Syndrome 53 Brentuximab Vedotin SGN 53 AVOREN 53 ASCO GI 53 Ereska 53 melphalan prednisone 53 WallFlex Biliary RX 53 multicentre prospective 53 relapsing multiple sclerosis 53 MYDICAR 53 Drug eluting stent 53 Phenoptin 53 HuMax EGFr 53 nab paclitaxel 53 desvenlafaxine succinate 53 carotid stents 53 Gynecologic Oncology Group 53 pharmacodynamics PD 53 maximally tolerated dose 53 treatment naïve genotype 53 ticagrelor 53 APEX AMI trial 53 severe hypercholesterolemia 53 ACAPODENE 53 GENASIS clinical 53 HBeAg negative patients 53 Initiate Phase 53 eluting stent 53 Rheos System 53 annual Transcatheter Cardiovascular 53 GRAVITAS trial 53 paclitaxel eluting coronary stent 53 PROMUS Stent 53 Dr. Kandzari 53 lacosamide 53 pharmacokinetic characteristics 53 huC# DM4 53 Connective Tissue Oncology 53 ruboxistaurin 53 Corporation NYSE BSX 53 Trofex 53 Subgroup analysis 53 blind placebo controlled 53 Acute Coronary Syndromes 53 Acute Stroke 53 Hepatocellular Carcinoma 53 registrational 53 ZYBRESTAT fosbretabulin 53 CTAP# Capsules 53 CABG surgeries 53 serum phosphorous 53 ISAR REACT 53 COPAXONE R 53 Completes Patient Enrollment 53 MGuard 53 Xelox 53 Nitinol Stent 53 TAXUS Express2 paclitaxel eluting 53 STICH trial 53 Phase IIb Trial 53 Self Expanding Stent 53 interferon gamma 1b 53 SUTENT ® 53 TM Everolimus Eluting 53 e HEALING 53 Second Pivotal Phase 53 TOLAMBA 53 Fondaparinux 53 multicentre randomized controlled 53 RoACTEMRA 53 confirmatory Phase 53 DAPT Study 53 pivotal bioequivalence 53 Systemic Sclerosis 53 Ranolazine 53 ozarelix 53 PEG PAL 53 induced macular edema 53 Endarterectomy 53 rFVIIa 53 HeFT 53 REYATAZ r 53 Heart Failure Patients 53 Controlled Trial 53 By JENNIFER LEARN 53 Dacogen injection 53 mg BID dose 53 NEUVENGE 53 CLL8 53 pertuzumab 53 acute coronary syndrome 53 CHARM Added 53 Pre RELAX AHF 53 Tolerability 53 randomized discontinuation trial 53 Phase II 53 Patient Enrollment 53 Observational Study 53 STENT 53 dacarbazine chemotherapy 53 Patients Enrolled 53 REVIVE TA 53 liver transplant recipients 53 RECIST Response Evaluation Criteria 53 ThermoDox ® 53 stable angina 53 Phase #b/#a 53 Randomised Study 53 PCI ExTRACT TIMI 53 ischemic cardiomyopathy 53 ASSERT 52 Randomized Double blind 52 Stenting Trial 52 PTNS 52 CURRENT OASIS 7 52 NATRECOR ® 52 ezetimibe simvastatin 52 Kaplan Meier analysis 52 EmbraceAC 52 icatibant 52 ularitide 52 KRN# 52 statistically significant efficacy 52 Rivaroxaban 52 adjuvant colon cancer 52 sunitinib Sutent 52 randomized controlled trials 52 initiated Phase Ib 52 label multicenter Phase 52 pharmacokinetic 52 budesonide MMX 52 lixisenatide 52 HGS ETR2 52 ACR# responses 52 Phase III randomized controlled 52 INTERCEPT platelets 52 INSPIRE Trial Phase III 52 KRAS mutations occur 52 pharmacodynamic profiles 52 RAPAFLO R 52 OHR/AVR# 52 QLT# 52 Patency 52 amrubicin 52 Aggressive Reduction 52 Imprime PGG 52 Xience 52 trastuzumab DM1 T DM1 52 Placebo Controlled Trial 52 VESTASYNC 52 Hsp# Inhibitor 52 GORE VIABAHN ® 52 beta blocker therapy 52 acute coronary syndromes ACS 52 AEGR 52 Taxus Element 52 Ambulatory Blood Pressure 52 ThermoDox 52 pain palliation 52 EXPAREL ™ 52 Polyp Prevention Trial 52 AA Amyloidosis 52 retrospective cohort study 52 Safinamide 52 observational studies 52 randomized controlled trial 52 cariprazine 52 Platinum Chromium 52 nesiritide 52 ascending dose 52 prucalopride 52 CALERIE 52 Aflibercept 52 tocilizumab 52 tolevamer 52 Efficacy Results 52 tolerability 52 varespladib 52 Taxus Liberte 52 ISEL 52 Celecoxib APC trial 52 histologically confirmed 52 Truvada tablets 52 XL# SAR# 52 Subgroup Analysis 52 plus prednisone 52 Express2 TM Paclitaxel Eluting 52 edoxaban 52 Cleviprex TM clevidipine 52 safety tolerability pharmacokinetic 52 metastatic hormone refractory 52 thrombus aspiration 52 blind randomized placebo 52 Placebo Controlled 52 prospective cohort 52 IMA# 52 ™ Everolimus Eluting 52 Zenvia 52 AACR IASLC Joint 52 TAXUS Liberte paclitaxel eluting 52 HPTN 52 Primary endpoints 52 eltrombopag 52 cediranib 52 Advanced Neuroendocrine Tumors 52 symptomatic BPH 52 Investigational Drug 52 XIENCE PRIME 52 Lung Cancer Trial 52 vicriviroc 52 atherothrombotic events 52 Epanova 52 heFH 52 Carotid Endarterectomy 52 LEP ETU 52 bivalirudin 52 iPrEx study 52 Phase IIA 52 briakinumab 52 Stent thrombosis 52 SEPET TM 52 Surgical Mesh 52 INCB# [003] 52 ATTRACT 52 ganetespib 52 retrospective cohort 52 ThermoDox R 52 Phase #/#a trial 52 RSD# oral 52 CLIRS trial 52 CELLO 52 Carfilzomib 52 BARACLUDE R 52 fluvastatin 52 novel VDA molecule 52 Angiox ® 52 blind randomized 52 alicaforsen enema 52 REVIVE Diabetes 52 Motesanib 52 Boston Scientific Taxus 52 rosuvastatin #mg 52 Hepatocellular Carcinoma HCC 52 Outpatient Setting 52 ThermoDox ® clinical 52 Tamibarotene 52 symptomatic VTE 52 Echocardiographic 52 APF# Phase 52 Adenoma Prevention 52 ASSERT trial 52 CIMZIA TM certolizumab pegol 52 Dose Ranging Study 52 Restenosis 52 Phase III multicenter 52 FOLOTYN ® 52 forodesine 52 Infarct 52 eprotirome 52 Genitourinary Cancers Symposium 52 Pivotal Phase II 52 BCX# 52 AACR #st Annual Meeting 52 Rasilez Tekturna 52 mycophenolate mofetil 52 Certican 52 JAK Inhibitor 52 Desvenlafaxine Succinate 52 ECASS 52 pharmacodynamic PD 52 glatiramer acetate 52 dose escalation study 52 pharmacokinetic pharmacodynamic 52 composite endpoint 52 stage IIIb IV 52 Randomized Clinical Trials 52 lubiprostone 52 Deforolimus 52 Clinical Trial Data 52 Pemetrexed 52 PFO closure 52 EMPHASIS HF trial 52 Efficacy

Back to home page